Related Experiment Videos
IgG subclass antibody response to hymenoptera venom
E A Pastorello1, C Incorvaia, D Vassellatti
12nd Department of Internal Medicine, University of Milan, School of Medicine, Milano, Italy.
New England and Regional Allergy Proceedings
|November 1, 1987
Summary
Venom immunotherapy increases IgG1 and IgG4 antibodies, crucial for protecting against insect stings. These antibody levels correlate with treatment effectiveness in allergic patients.
Area of Science:
- Immunology
- Allergology
- Toxicology
Background:
- Venom immunotherapy (VIT) offers protection against hymenoptera stings.
- Elevated venom-specific IgG antibodies are linked to clinical protection, particularly with Yellow Jacket venom.
- IgG subclasses, especially IgG4, increase during VIT, with IgG1 potentially regulating IgE levels.
Purpose of the Study:
- To investigate the changes in venom-specific IgG subclasses (IgG1, IgG2, IgG4) during Honey Bee venom immunotherapy.
- To explore the relationship between IgG subclass levels and clinical outcomes in patients undergoing VIT.
Main Methods:
- Patients undergoing Honey Bee venom immunotherapy were monitored.
- Levels of venom-specific IgG1, IgG2, and IgG4 antibodies were measured.
- Changes in antibody levels were analyzed in relation to treatment duration.
Main Results:
- A significant increase in venom-specific IgG1 and IgG4 antibodies was observed.
- IgG2 showed an insignificant increase in some patients.
- Prolonged treatment led to persistently high IgG4 levels and decreasing IgG1 levels.
Conclusions:
- Honey Bee venom immunotherapy effectively modulates IgG subclass responses.
- IgG1 and IgG4 antibodies play significant roles in the immunological mechanisms of VIT.
- Sustained high IgG4 and declining IgG1 levels may indicate long-term immune adaptation.